175 related articles for article (PubMed ID: 36106577)
81. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
[TBL] [Abstract][Full Text] [Related]
82. Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma.
Stephen S; Morrissey KA; Benoit BM; Kim EJ; Vittorio CC; Nasta SD; Showe LC; Wysocka M; Rook AH
Am J Hematol; 2012 Feb; 87(2):226-8. PubMed ID: 22189940
[TBL] [Abstract][Full Text] [Related]
83. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
[TBL] [Abstract][Full Text] [Related]
84. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
[TBL] [Abstract][Full Text] [Related]
85. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
[TBL] [Abstract][Full Text] [Related]
86. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.
Palmieri D; Lockman PR; Thomas FC; Hua E; Herring J; Hargrave E; Johnson M; Flores N; Qian Y; Vega-Valle E; Taskar KS; Rudraraju V; Mittapalli RK; Gaasch JA; Bohn KA; Thorsheim HR; Liewehr DJ; Davis S; Reilly JF; Walker R; Bronder JL; Feigenbaum L; Steinberg SM; Camphausen K; Meltzer PS; Richon VM; Smith QR; Steeg PS
Clin Cancer Res; 2009 Oct; 15(19):6148-57. PubMed ID: 19789319
[TBL] [Abstract][Full Text] [Related]
87. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
88. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate.
Hu Y; Lu W; Chen G; Zhang H; Jia Y; Wei Y; Yang H; Zhang W; Fiskus W; Bhalla K; Keating M; Huang P; Garcia-Manero G
Blood; 2010 Oct; 116(15):2732-41. PubMed ID: 20566897
[TBL] [Abstract][Full Text] [Related]
89. Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood.
Liu L; Detering JC; Milde T; Haefeli WE; Witt O; Burhenne J
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Aug; 964():212-21. PubMed ID: 24636840
[TBL] [Abstract][Full Text] [Related]
90. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
91. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
[TBL] [Abstract][Full Text] [Related]
92. HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.
Alcitepe İ; Salcin H; Karatekin İ; Kaymaz BT
Med Oncol; 2022 Oct; 39(12):257. PubMed ID: 36224430
[TBL] [Abstract][Full Text] [Related]
93. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
[TBL] [Abstract][Full Text] [Related]
94. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
95. Effect of Histone Deacetylase Inhibition on the Expression of Multidrug Resistance-associated Protein 2 in a Human Placental Trophoblast Cell Line.
Duan HY; Ma D; Zhou KY; Wang T; Zhang Y; Li YF; Wu JL; Hua YM; Wang C
Chin Med J (Engl); 2017 Jun; 130(11):1352-1360. PubMed ID: 28524836
[TBL] [Abstract][Full Text] [Related]
96. Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis.
Mo H; Zhang R; Chen Y; Li S; Wang Y; Zou W; Lin Q; Zhao DG; Du Y; Zhang K; Ma YY
Eur J Med Chem; 2022 Dec; 243():114705. PubMed ID: 36215854
[TBL] [Abstract][Full Text] [Related]
97. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
98. Vorinostat approved for rare lymphoma.
Thompson CA
Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
[No Abstract] [Full Text] [Related]
99. A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target.
Ibhazehiebo K; Gavrilovici C; de la Hoz CL; Ma SC; Rehak R; Kaushik G; Meza Santoscoy PL; Scott L; Nath N; Kim DY; Rho JM; Kurrasch DM
Brain; 2018 Mar; 141(3):744-761. PubMed ID: 29373639
[TBL] [Abstract][Full Text] [Related]
100. Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles.
Meka AK; Jenkins LJ; Dàvalos-Salas M; Pujara N; Wong KY; Kumeria T; Mariadason JM; Popat A
Pharmaceutics; 2018 Dec; 10(4):. PubMed ID: 30562958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
